Stockreport

Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplif...

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF Cyclin E1 molecular glue degraders (MGDs) represent a potential novel therapeutic approach by directly and selectively targeting a frequently amplified non-enzymatic dri [Read more]